Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) by Saiag, P. et al.
Annals of Oncology 27: 1947–1953, 2016
doi:10.1093/annonc/mdw291
Published online 8 August 2016
Prospective assessment of a gene signature potentially
predictive of clinical beneﬁt in metastatic melanoma
patients following MAGE-A3 immunotherapeutic
(PREDICT)
P. Saiag1*, R. Gutzmer2, P. A. Ascierto3, M. Maio4, J.-J. Grob5, P. Murawa6, B. Dreno7, M. Ross8,
J. Weber9, A. Hauschild10, P. Rutkowski11, A. Testori12, E. Levchenko13, A. Enk14, L. Misery15,
C. Vanden Abeele16, I. Vojtek16, O. Peeters16,†, V. G. Brichard16,‡ & P. Therasse16,§
1General Dermatology and Oncology Service, Ambroise-Paré Hospital, AP-HP, University of Versailles-Saint-Quentin-en-Yvelines, Boulogne, France; 2Skin Cancer Center
Hannover, Hannover Medical School, Hannover, Germany; 3National Institute for Tumors Foundation ‘G. Pascale’, Napoli; 4Medical Oncology and Immunotherapy,
Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; 5Department of Dermatology and Skin Cancers, La Timone APHM Hospital,
Aix-Marseille University, Marseille, France; 6Department of Biochemistry and Molecular Biology, Poznan´ University of Medical Sciences, Poznan´, Poland; 7Dermatology
Clinic, Hôtel-Dieu Hospital, CHU Nantes, Nantes, France; 8Department of Surgical Oncology, UTMD Anderson Cancer Center, Houston; 9Mofﬁtt Cancer Center, Tampa,
USA; 10Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany; 11Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria
Sklodowska-Curie Memorial Center and Institute of Oncology, Warsaw, Poland; 12Melanoma and Soft Tissue Sarcoma Division, European Institute of Oncology, Milan, Italy;
13Petrov Research Institute of Oncology, St Petersburg, Russian Federation; 14Department of Dermatology, University of Heidelberg, Heidelberg, Germany; 15Department
of Dermatology, University Hospital of Brest, Brest, France; 16GSK Vaccines, Rixensart, Belgium
Received 10 January 2016; revised 26 May 2016; accepted 20 July 2016
Background: Genomic proﬁling of tumor tissue may aid in identifying predictive or prognostic gene signatures (GS) in
some cancers. Retrospective gene expression proﬁling of melanoma and non-small-cell lung cancer led to the character-
ization of a GS associated with clinical beneﬁt, including improved overall survival (OS), following immunization with the
MAGE-A3 immunotherapeutic. The goal of the present study was to prospectively evaluate the predictive value of the pre-
viously characterized GS.
Patients and methods: An open-label prospective phase II trial (‘PREDICT’) in patients with MAGE-A3-positive unre-
sectable stage IIIB-C/IV-M1a melanoma.
Results: Of 123 subjects who received the MAGE-A3 immunotherapeutic, 71 (58.7%) displayed the predictive GS (GS
+). The 1-year OS rate was 83.1%/83.3% in the GS+/GS− populations. The rate of progression-free survival at 12
months was 5.8%/4.1% in GS+/GS− patients. The median time-to-treatment failure was 2.7/2.4 months (GS+/GS−).
There was one complete response (GS−) and two partial responses (GS+). The MAGE-A3 immunotherapeutic was simi-
larly immunogenic in both populations and had a clinically acceptable safety proﬁle.
Conclusion: Treatment of patients with MAGE-A3-positive unresectable stage IIIB-C/IV-M1a melanoma with the
MAGE-A3 immunotherapeutic demonstrated an overall 1-year OS rate of 83.5%. GS− and GS+ patients had similar
1-year OS rates, indicating that in this study, GS was not predictive of outcome. Unexpectedly, the objective response
rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic.
Investigation of a GS to predict clinical beneﬁt to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another
melanoma study.This study is registered at www.clinicatrials.gov NCT00942162.
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